Vol. 5, Issue 5 (2016)
Over expression of P27 protein from CDKN1B gene in patients with invasive bladder transitional cell carcinoma
Dr. Suha Abdullah Al-Fakhar, Dr. Saad Hasan Mohammed Ali, Ahmed Abbas Abed AL-Zuwaid, Dr. Shakir H. Mohammed AL-Alwany
Background: Urinary bladder cancer is the fifth most common cancer in the western world. P27 is an enzyme inhibitor encoded by the CDKN1B gene in humans that belongs to the Cip /Kip family of cyclin-dependent kinase (Cdk) proteins. This protein prevents activation of cyclin E-CDK2 or cyclin D-CDK4 complexes, and thus controlling cell cycle progression at G1. Objective: To assess the relation of over expression of P27 protein to translational in a group of invasive bladder transitional cell carcinoma as compared to their healthy counterparts. Materials and Methods: Forty-two formalin-fixed, paraffin embedded bladder tissues were enrolled in this study; biopsies from 30 invasive bladder transitional cell carcinomas well as 12 apparently normal bladder autopsies were included as a control groups. The translational protein of the expressed P27 gene was evaluated by immunohistochemistry. Results: Positive immunohistochemical reactions for P27 protein were observed in 15 cases (50.0%) of invasive bladder transitional cell carcinoma while none of bladder tissues in control group revealed P27 immunostaining reactions. Statistically, the difference between the percentages of positive P27 protein-IHC reactions in bladder cancer group with control group was highly significant (P value = 0.002). Conclusions: The highly significant translational over expression of P27 in our series of invasive bladder transitional cell carcinoma could importantly point for a role for derangement in that protein levels in the carcinogenesis of a subset of such cancer in our country.
How to cite this article:
Dr. Suha Abdullah Al-Fakhar, Dr. Saad Hasan Mohammed Ali, Ahmed Abbas Abed AL-Zuwaid, Dr. Shakir H. Mohammed AL-Alwany. Over expression of P27 protein from CDKN1B gene in patients with invasive bladder transitional cell carcinoma. Pharma Innovation 2016;5(5):107-111.